Global Blood Cancer Therapeutics Market Will Grow at a CAGR of Over 8% During 2019-2023 | Technavio

LONDON–(BUSINESS WIRE)–lt;a href=”” target=”_blank”gt;#Researchlt;/agt;–Technavio has announced the release of their research report on the
Global Blood Cancer Therapeutics Market for the forecast period
2019-2023. This blood cancer therapeutics market analysis report
segments the market by type (leukemia, lymphoma, and myeloma) and
geography (Asia, Europe, North America, and ROW).

Global blood cancer therapeutics market size will grow by USD 12.63
billion during 2019-2023, at a CAGR of over 8%. There is an increase in
advances in the research of regenerative therapies due to their curative
nature. Multiple targeted therapies such as CAR T-cell therapies have
been approved and are gaining traction as they effectively treat
leukemia and lymphoma. These therapies are also in the final stages of
clinical trials for other cancer indications. The presence of vendors
with novel therapies in the early stages of clinical trials for CAR
T-cell therapies and gene therapies for blood cancer is also increasing.
This is resulting in the development of sufficient therapeutics for
blood cancer, which will lead to market growth.

Growing adoption of therapeutics

Various organizations are focusing on creating awareness about the
existence of novel therapies with the potential to cure the disease.
They are also making efforts to create awareness about the disease in
major countries of Europe. With the global increase in the prevalence of
cancer, there is an increase in the number of patients undergoing
diagnosis and opting for treatment for conditions such as myeloma.
Vendors and government organizations are coming up with patient
assistance programs to deliver the therapy at an affordable price. This
is leading to increased patient adherence and adoption of therapeutics
for the treatment.

for a FREE sample
and get selected illustrations,
table of contents, list of exhibits, and example pages from this report.

“The presence of various large pharmaceutical vendors with novel
therapies in the late stages of clinical trials and a strong pipeline
will drive the blood cancer therapeutics market growth in North America.
Additionally, the high influx of patients being diagnosed and seeking
treatment, encouraged by the increasing number of awareness programs
conducted by vendors and various organizations will also drive the
growth of the market in North America,” says an analyst at Technavio.

Numerous vendors and organizations are introducing programs to reduce
the cost burden on patients by minimizing costs associated with
therapeutics. Also, government organizations are ensuring the delivery
of treatment at an affordable price by providing funding for the
development of healthcare infrastructure. As a result, the healthcare
infrastructure in nations such as China and India is advancing at a
significant rate. This will attract more patients and boost the adoption
of blood cancer therapeutics.

snapshot of the report
for a more detailed overview of
the market and the segmentation covered in this report

This blood cancer therapeutics industry research report provides an
in-depth analysis of the major drivers, upcoming trends, and challenges
that will impact market growth over the forecast period. The report
analyzes the competitive landscape and offers details on several blood
cancer therapeutics manufacturers including –

  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Takeda Pharmaceutical Company Limited

Some of the key topics covered in the report include:

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

Market Sizing

  • Market definition
  • Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

  • Regional comparison
  • Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Competitive scenario

About Technavio

is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.
Technavio’s report library consists of more than 10,000 reports covering
800 technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100 Fortune
500 companies.

Please contact our media team at
for more information.


Technavio Research
Jesse Maida
Media & Marketing Executive
+1 844 364 1100
UK: +44 203 893 3200